Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10004783HBVENSG00000116329.12protein_codingOPRD1NoNo4985P41143
TVIS30074531HIVENSG00000116329.12protein_codingOPRD1NoNo4985P41143
TVIS30022908HIVENSG00000116329.12protein_codingOPRD1NoNo4985P41143
TCGA Plot Options
Drug Information
GeneOPRD1
DrugBank IDDB00704
Drug NameNaltrexone
Target IDBE0000420
UniProt IDP41143
Regulation Typeantagonist
PubMed IDs11752352; 15788780; 17661275; 17487229; 9673788; 9040115
CitationsChen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Roy S, Guo X, Kelschenbach J, Liu Y, Loh HH: In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J Neurosci. 2005 Mar 23;25(12):3229-33.@@Barrios de Tomasi E, Juarez-Gonzalez J: [Opioid antagonists and alcohol consumption]. Rev Neurol. 2007 Aug 1-15;45(3):155-62.@@Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME: Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008 Feb;33(3):653-65. Epub 2007 May 9.@@Herz A: Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol. 1998 Mar;76(3):252-8.@@Herz A: Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997 Jan;129(2):99-111.
GroupsApproved; Investigational; Vet_approved
Direct ClassificationPhenanthrenes and derivatives
SMILES[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O
PathwaysNaltrexone Action Pathway
PharmGKBPA450588
ChEMBLCHEMBL19019